阿瑞匹坦在医保范围内吗？

The original drug aprepitant is a neurokinin-1 (NK-1) receptor blocker developed by Merck. It can highly selectively block the NK-1 receptor and bind tightly to it, thereby inhibiting vomiting caused by chemotherapy drugs. Aprepitant is the world's first approved NK-1 receptor antagonist antiemetic drug and the first pitant drug to be marketed in China. It is used to prevent acute and delayed nausea and vomiting during initial and repeated treatments of highly emetogenic anti-tumor chemotherapy. Is it covered by medical insurance?

According to Medical Companion Travel, aprepitant is not included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2020)" and is therefore no longer covered by medical insurance. Because it is not a medical insurance drug, the price of aprepitant in China is still relatively high. The general specifications are 0.125gx1 capsule + 80mgx2 capsules, each box sells for about $600. Patients who need medication can also choose other versions of aprepitant on sale. For details, please contact the medical companion travel service for consultation.

Chemotherapy is an important treatment for many cancer patients. However, chemotherapy is accompanied by adverse reactions such as hair loss, nausea, and vomiting. According to research, more than 75% of chemotherapy drugs can cause nausea and vomiting. The pain caused by chemotherapy often makes patients hesitate to continue treatment. Some even lose confidence in life and give up the opportunity for treatment. Professor Wang Jie, chief physician of Beijing Medical University Cancer Hospital and member of the Standing Committee of the Lung Cancer Professional Committee of the Chinese Anti-Cancer Association, said that the prevention and treatment of such adverse reactions is very important, and its importance is no less than the chemotherapy regimen itself. As a first-line drug and recommended drug for preventing nausea and vomiting caused by highly emetogenic anti-tumor chemotherapy, it has been unanimously recommended by authoritative European and American guidelines such as the National Comprehensive Cancer Network Clinical Application Guidelines (NCCN).

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.